Get the Stockscreener App
0.795
1.66%
0.013
After Hours:
.80
0.005
+0.63%
Cytosorbents Corp stock is traded at $0.795, with a volume of 71,694.
It is up +1.66% in the last 24 hours and down -14.89% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$0.782
Open:
$0.7907
24h Volume:
71,694
Relative Volume:
0.43
Market Cap:
$49.90M
Revenue:
$33.79M
Net Income/Loss:
$-18.67M
P/E Ratio:
-2.2194
EPS:
-0.3582
Net Cash Flow:
$-19.17M
1W Performance:
-6.49%
1M Performance:
-14.89%
6M Performance:
-21.29%
1Y Performance:
-21.29%
1-Day Range:
$0.7907
$0.8287
1-Week Range:
$0.7712
$0.86
52-Week Range:
$0.7101
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.795 | 49.08M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
123.62 | 216.79B | 43.84B | 13.90B | 6.78B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.72 | 149.02B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
356.24 | 141.06B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
90.70 | 116.68B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.45 | 49.01B | 5.69B | 1.41B | 577.90M | 6.9828 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights - BioSpace
Cytosorbents (CTSO) to Release Quarterly Earnings on Thursday - MarketBeat
Is Cytosorbents Corporation stock positioned well for digital economyJuly 2025 Sector Moves & Stepwise Trade Execution Plans - newser.com
Can machine learning forecast Cytosorbents Corporation recoveryJuly 2025 Analyst Calls & Verified Stock Trade Ideas - newser.com
Published on: 2025-10-31 00:03:46 - newser.com
Is a relief rally coming for Cytosorbents Corporation holdersJuly 2025 Momentum & Daily Profit Focused Screening - newser.com
CytoSorbents’ STAR Registry: A Closer Look at the Latest Clinical Study Update - TipRanks
CytoSorbents (NASDAQ: CTSO) sets Nov. 13 results call at 4:30 PM ET and webcast details - Stock Titan
What MACD and RSI say about Cytosorbents CorporationTrade Ideas & Fast Moving Trade Plans - newser.com
Using economic indicators to assess Cytosorbents Corporation potential2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
Can momentum traders help lift Cytosorbents CorporationRisk Management & Real-Time Buy Signal Alerts - newser.com
Will breakout in Cytosorbents Corporation lead to full recovery2025 Technical Patterns & Consistent Income Trade Recommendations - newser.com
Will Cytosorbents Corporation (HQE1) stock keep high P E multiples2025 Price Action Summary & Smart Investment Allocation Tips - newser.com
In Memoriam: Dr. Robert Hawes Bartlett (1939-2025)Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer - PR Newswire
Will Cytosorbents Corporation stock recover faster than marketPortfolio Performance Report & High Return Trade Opportunity Guides - newser.com
Published on: 2025-10-27 17:34:50 - newser.com
Cytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care? - TipRanks
Published on: 2025-10-27 06:48:52 - newser.com
Why Cytosorbents Corporation (HQE1) stock remains top ratedWeekly Trading Summary & Long-Term Investment Growth Plans - newser.com
Using data tools to time your Cytosorbents Corporation exitQuarterly Earnings Summary & Community Consensus Stock Picks - newser.com
Why Cytosorbents Corporation (HQE1) stock is trending on social mediaShort Setup & Accurate Technical Buy Alerts - newser.com
Leading vs lagging indicators on Cytosorbents Corporation performanceJuly 2025 Short Interest & Consistent Income Trade Recommendations - newser.com
Using flow based indicators on Cytosorbents CorporationWeekly Trade Analysis & Consistent Income Trade Ideas - newser.com
Published on: 2025-10-25 13:24:21 - newser.com
Published on: 2025-10-25 08:25:22 - newser.com
Published on: 2025-10-24 04:48:34 - newser.com
Published on: 2025-10-23 05:04:10 - newser.com
How Cytosorbents Corporation (HQE1) stock responds to bond marketPortfolio Performance Report & Stock Market Timing Techniques - newser.com
Why retail traders accumulate Cytosorbents Corporation (HQE1) stockTrade Volume Report & Scalable Portfolio Growth Methods - newser.com
Published on: 2025-10-20 17:17:13 - newser.com
Will Cytosorbents Corporation (HQE1) stock beat value stocks2025 Dividend Review & Daily Chart Pattern Signal Reports - newser.com
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
14.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):